Clever Culture Systems (ASX: CC5) is an Australian biotechnology leader developing AI-powered microbiology solutions. Their flagship product, the Automated Plate Assessment System (APAS), addresses a critical global challenge in pharmaceutical manufacturing where millions of culture plates are manually processed yearly. APAS uses patent-protected machine learning and intelligent imaging to automate the interpretation and reporting of microbial growth on culture plates, supporting the sterility and compliance requirements for safe production of drugs.

Following a decade of development, Clever Culture Systems launched APAS® in 2024. Major pharmaceutical companies including AstraZeneca, Bristol Myers Squibb, and CDMO such as Thermo Fisher Scientific have adopted APAS. With blue-chip customers in place and additional sales completed, there is a substantial market opportunity for APAS® to become the new standard in pharmaceutical microbiology automation.